Featured Articles

Sorrento Therapeutics, Inc. and Mount Sinai Health System have agreed to join forces in the investigation and development of an antibody cocktail (COVI-SHIELD) to potentially treat…
Read More...

Schreiner MediPharm has developed a compact Booklet-Label for a needle protection system used in an international phase III clinical trial conducted by pharmaceutical corporation…
Read More...

AstraZeneca and the University of Oxford announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at…
Read More...

Novartis announced plans to initiate a Phase III clinical trial to study canakinumab in patients with COVID-19 pneumonia. The CAN-COVID trial will examine the efficacy of utilizing…
Read More...

Gilead Sciences, Inc. announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigational antiviral remdesivir in…
Read More...

Griffith University researchers have joined forces with scientists from Indian Immunologicals Limited (IIL), a leading vaccines manufacturing company based in Hyderabad, India to…
Read More...

Novartis announced that the US Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to Kymriah (tisagenlecleucel), for an investigational…
Read More...

Gilead Sciences, Inc. Kite, a Gilead Company, and oNKo-innate announced the companies have entered into a three-year cancer immunotherapy research collaboration to support discovery and…
Read More...

Intensity Therapeutics announced it has entered into a clinical trial collaboration agreement with Bristol Myers Squibb Company. The program will evaluate the safety and efficacy of…
Read More...

The U.S. Food and Drug Administration approved Koselugo (selumetinib) for the treatment of pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1), a genetic…
Read More...

Acceleron Pharma Inc. announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sotatercept for the treatment of patients with…
Read More...

Global biotherapeutics leader, CSL Behring and innovative human antibody development company SAB Biotherapeutics (SAB) announced their partnership to combat the coronavirus pandemic…
Read More...

Gilead Sciences, Inc. and Second Genome announced that the companies have entered into a four-year strategic collaboration to identify biomarkers associated with clinical response in up…
Read More...

GlaxoSmithKline plc and Vir Biotechnology, Inc. announced they have signed a binding agreement to enter into a collaboration to research and develop solutions for coronaviruses,…
Read More...

Biotest, BPL, LFB, and Octapharma have joined an alliance formed by CSL Behring and Takeda Pharmaceutical Company Limited to develop a potential plasma-derived therapy for treating…
Read More...

Sorrento Therapeutics, Inc. announced it has entered into a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento’s…
Read More...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with…
Read More...

AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) has been approved in Japan for the treatment of patients with hyperkalaemia (elevated levels of potassium in the blood). The…
Read More...

Sorrento Therapeutics, Inc. announced it has been working on a novel decoy cellular vaccine for COVID-19 (STI-6991) and is in active discussions with the FDA’s Center for Biologics…
Read More...

Merck, known as MSD outside the United States and Canada, announced top-line efficacy results from two ongoing pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and…
Read More...